Navigation Links
Antifolate in Medical News

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this phase ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

...treatment regimens, including an autologous stem cell transplant for some patients. Designed to be selectively transported into tumor cells, the novel antifolate pralatrexate accumulates to high concentrations in the tumor cell, inhibiting DNA synthesis. A total of 115 patients were enrolled into this ...

Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Reports Third Quarter 2007 Financial Results

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Antifolate Drugs may Be Effective in Treating P Vivax Malaria

...Malaria and Leishmaniasis Control Programme in Pakistan, have revealed that antifolate drugs may be effective in treating P vivax malaria. Toby Leslie, M.Sc., and colleagues tested the relative efficacy and safety of two antifolate drugs (sulfadoxine-pyrimethamine and chlorproguanil-dapsone) against P viva...
Antifolate in Medical Technology

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer

... to focus solely on oncology assets. He led the licensing effort to acquire both oncology products currently in their portfolio: pralatrexate, a novel antifolate currently in a registration trial in peripheral T-cell lymphoma, and RH1, currently in a Phase 1 trial for solid tumors. Before Allos, Mr. Malek held ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... with chemotherapy. J Clin Oncol 2004; 22:1589-97. (3) Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66:431-...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma

...ollment in a Phase 1, open-label, multi-center study of the Company's novel antifolate PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patie...ancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with rela...

Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

...(tm) (talotrexin) for Injection Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talve...more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR,...
Antifolate in Biological Technology

Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is...

Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference

...n vitro. PDX in NSCLC (Phase 1) The poster entitled "Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in ...ancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients ...

Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...

Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference

...and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investig...
Other Tags
(Date:7/23/2014)... On July 21, 2014, My Positive Perspective host ... for an episode that spoke about the group Darkness to ... to talk some about the formation of the group, Tracey ... was started right here in Charleston, originally it was called ... survivors of sexual abuse. Their purpose has shifted to educating ...
(Date:7/23/2014)... As the push for marriage ... understanding the unique circumstances and special needs of ... To help lesbians pursue parenthood with knowledge and ... hosting a free, educational event about pregnancy and ... lesbian couples, not knowing legal and medical options ...
(Date:7/23/2014)... ANTONIO (July 22, 2014) Mouse models of human ... dramatic tumor shrinkage without damage to surrounding tissues, researchers ... at The University of Texas Health Science Center at ... intellectual property on results of the study, which is ... Late diagnosis, low survival , Oral squamous ...
(Date:7/23/2014)... Follow us on LinkedIn ... proportions in both developed and developing countries alike. Rising ... growing preference for processed food, and sedentary lifestyles present ... regarded a disease by itself, obesity is known to ... diabetes, hypertension, cardiovascular risks as well as cancer. The ...
(Date:7/23/2014)... 23, 2014 The Case Management Society of ... Day on the Hill, a one-day event that will bring ... awareness to Congress on the importance of case management to ... on September 10, 2014, at the U.S. Capitol Visitors Center ... Hill provides participants with the opportunity to play a direct ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Airs Episode to Raise Attention to the Group Darkness to Light 2Health News:Gay Women’s Gathering ™ in Chicago: An Evening about Lesbian Pregnancy 2Health News:Gay Women’s Gathering ™ in Chicago: An Evening about Lesbian Pregnancy 3Health News:Gay Women’s Gathering ™ in Chicago: An Evening about Lesbian Pregnancy 4Health News:Anti-pain agent shrinks oral cancers, leaves healthy tissues alone 2Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 2Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 3Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 4Health News:CMSA Launches Registration for the 2014 Day on the Hill 2
(Date:7/22/2014)... A new study that examined the survival rates ... bycatch in commercial longline fishing operations found large ... bigeye thresher, dusky, and scalloped hammerhead being the ... University of Miami (UM) Rosenstiel School of,Marine and ... Science and Policy, provides,new information to consider for ...
(Date:7/22/2014)... collaboration known as the ,1000 Bull Genomes Project, aims ... dairy cattle while also improving animal health and welfare. ... sequencing the whole genomes of 234 individual bulls whose ... are reported in the journal Nature Genetics . ... this information to reduce or eliminate hereditary diseases and ...
(Date:7/22/2014)... from the National Institute of Standards and Technology ... a dramatically improved technique for analyzing biological cells ... The new NIST technique is an advanced form ... one that delivers signals that are 10,000 times ... 100 times stronger than obtained from comparable "coherent ...
Breaking Biology News(10 mins):New study reveals vulnerability of sharks as collateral damage in commercial fishing 2Whole-genome sequencing of bulls in key beef and dairy breeds 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3
Other Contents